apl 2 market size forecast and emerging insight

“APL-2 Market Size, Forecast, and Emerging Insight - 2032” report provides comprehensive insights about APL-2 for Complement 3 Glomerulopathy (C3G) in the seven major markets. A detailed picture of the APL-2 for C3G in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the APL-2 for C3G. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the APL-2 market forecast analysis for C3G in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in C3G.

Drug Summary

Apellis’ Pegcetacoplan (APL-2) is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. It is a 15-amino acid cyclic peptide conjugated to each end of a linear polyethylene glycol molecule that binds to C3 and C3b, directly preventing activation of C3, C5, and the alternative pathway. The company believes this approach can regulate uncontrolled or excessive complement activation in several debilitating diseases, including those within hematology, ophthalmology, and nephrology. As per the company’s research, the drug has the potential to be a best-in-class and first-in-class treatment that may address the limitations of existing treatment options or provide a treatment option where today there is none.

In October 2020, the company initiated the Phase II (NOBLE) trial in up to 12 patients with post-kidney transplant recurrence of C3G or IC-MPGN. In September 2021, the first patients dosed in the NOBLE trial. In June 2022, the first patient was dosed in the VALIANT Phase III study investigating pegcetacoplan in C3G. Pegcetacoplan (marketed as EMPAVELI) is approved in the United States for treating adults with paroxysmal nocturnal hemoglobinuria. Currently, the drug is evaluated in a Phase III trial for C3G patients. 

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the APL-2 description, mechanism of action, dosage and administration, research and development activities in Complement 3 Glomerulopathy (C3G).
• Elaborated details on APL-2 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the APL-2 research and development activities in C3G across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around APL-2.
• The report contains forecasted sales of APL-2 for C3G till 2032.
• Comprehensive coverage of the late-stage emerging therapies for C3G.
• The report also features the SWOT analysis with analyst views for APL-2 in C3G.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

APL-2 Analytical Perspective by DelveInsight

In-depth APL-2 Market Assessment

This report provides a detailed market assessment of APL-2 for Complement 3 Glomerulopathy (C3G) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

APL-2 Clinical Assessment

The report provides the clinical trials information of APL-2 for C3G covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Complement 3 Glomerulopathy (C3G) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence APL-2 dominance.
• Other emerging products for C3G are expected to give tough market competition to APL-2 and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of APL-2 in C3G.
• Our in-depth analysis of the forecasted sales data of APL-2 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the APL-2 in C3G. 

Key Questions

• What is the product type, route of administration and mechanism of action of APL-2?
• What is the clinical trial status of the study related to APL-2 in Complement 3 Glomerulopathy (C3G) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the APL-2 development?
• What are the key designations that have been granted to APL-2 for C3G?
• What is the forecasted market scenario of APL-2 for C3G?
• What are the forecasted sales of APL-2 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to APL-2 for C3G?
• Which are the late-stage emerging therapies under development for the treatment of C3G?